FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164521421> ?p ?o ?g. }

• W2164521421 endingPage "36" @default.
• W2164521421 startingPage "29" @default.
• W2164521421 abstract "Background Preconception-initiated low-dose aspirin might positively affect pregnancy outcomes, but this possibility has not been adequately assessed. Our aim was to investigate whether low-dose aspirin improved livebirth rates in women with one to two previous pregnancy losses. Methods In this multicentre, block-randomised, double-blind, placebo-controlled trial, women aged 18–40 years who were attempting to become pregnant were recruited from four medical centres in the USA. Participants were stratified by eligibility criteria—the original stratum was restricted to women with one loss at less than 20 weeks' gestation during the previous year, whereas the expanded stratum included women with one to two previous losses, with no restrictions on gestational age or time of loss. Women were block-randomised by centre and eligibility stratum in a 1:1 ratio. Preconception-initiated daily low-dose aspirin (81 mg per day) plus folic acid was compared with placebo plus folic acid for up to six menstrual cycles; for women who conceived, study treatment continued until 36 weeks' gestation. Participants, trial staff, and investigators were masked to the assigned treatment. The primary outcome was livebirth rate, which was analysed by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00467363. Findings Overall, 1228 women were recruited and randomly assigned between June 15, 2007, and July 15, 2011, 1078 of whom completed the trial and were included in the analysis (535 in the low-dose aspirin group and 543 in the placebo group). 309 (58%) women in the low-dose aspirin group had livebirths, compared with 286 (53%) in the placebo group (p=0·0984; absolute difference in livebirth rate 5·09% [95% CI −0·84 to 11·02]). Pregnancy loss occurred in 68 (13%) women in the low-dose aspirin group, compared with 65 (12%) women in the placebo group (p=0·7812). In the original stratum, 151 (62%) of 242 women in the low-dose aspirin group had livebirths, compared with 133 (53%) of 250 in the placebo group (p=0·0446; absolute difference in livebirth rate 9·20% [0·51 to 17·89]). In the expanded stratum, 158 (54%) of 293 women in the low-dose aspirin group and 153 (52%) of 293 in the placebo group had livebirths (p=0·7406; absolute difference in livebirth rate 1·71% [−6·37 to 9·79]). Major adverse events were similar between treatment groups. Low-dose aspirin was associated with increased vaginal bleeding, but this adverse event was not associated with pregnancy loss. Interpretation Preconception-initiated low-dose aspirin was not significantly associated with livebirth or pregnancy loss in women with one to two previous losses. However, higher livebirth rates were seen in women with a single documented loss at less than 20 weeks' gestation during the previous year. Low-dose aspirin is not recommended for the prevention of pregnancy loss. Funding Eunice Kennedy Shriver National Institute of Child Health and Human Development (US National Institutes of Health). Preconception-initiated low-dose aspirin might positively affect pregnancy outcomes, but this possibility has not been adequately assessed. Our aim was to investigate whether low-dose aspirin improved livebirth rates in women with one to two previous pregnancy losses. In this multicentre, block-randomised, double-blind, placebo-controlled trial, women aged 18–40 years who were attempting to become pregnant were recruited from four medical centres in the USA. Participants were stratified by eligibility criteria—the original stratum was restricted to women with one loss at less than 20 weeks' gestation during the previous year, whereas the expanded stratum included women with one to two previous losses, with no restrictions on gestational age or time of loss. Women were block-randomised by centre and eligibility stratum in a 1:1 ratio. Preconception-initiated daily low-dose aspirin (81 mg per day) plus folic acid was compared with placebo plus folic acid for up to six menstrual cycles; for women who conceived, study treatment continued until 36 weeks' gestation. Participants, trial staff, and investigators were masked to the assigned treatment. The primary outcome was livebirth rate, which was analysed by intention to treat. The trial is registered with ClinicalTrials.gov, number NCT00467363. Overall, 1228 women were recruited and randomly assigned between June 15, 2007, and July 15, 2011, 1078 of whom completed the trial and were included in the analysis (535 in the low-dose aspirin group and 543 in the placebo group). 309 (58%) women in the low-dose aspirin group had livebirths, compared with 286 (53%) in the placebo group (p=0·0984; absolute difference in livebirth rate 5·09% [95% CI −0·84 to 11·02]). Pregnancy loss occurred in 68 (13%) women in the low-dose aspirin group, compared with 65 (12%) women in the placebo group (p=0·7812). In the original stratum, 151 (62%) of 242 women in the low-dose aspirin group had livebirths, compared with 133 (53%) of 250 in the placebo group (p=0·0446; absolute difference in livebirth rate 9·20% [0·51 to 17·89]). In the expanded stratum, 158 (54%) of 293 women in the low-dose aspirin group and 153 (52%) of 293 in the placebo group had livebirths (p=0·7406; absolute difference in livebirth rate 1·71% [−6·37 to 9·79]). Major adverse events were similar between treatment groups. Low-dose aspirin was associated with increased vaginal bleeding, but this adverse event was not associated with pregnancy loss. Preconception-initiated low-dose aspirin was not significantly associated with livebirth or pregnancy loss in women with one to two previous losses. However, higher livebirth rates were seen in women with a single documented loss at less than 20 weeks' gestation during the previous year. Low-dose aspirin is not recommended for the prevention of pregnancy loss." @default.
• W2164521421 created "2016-06-24" @default.
• W2164521421 creator A5003436141 @default.
• W2164521421 creator A5003758047 @default.
• W2164521421 creator A5009660168 @default.
• W2164521421 creator A5010698227 @default.
• W2164521421 creator A5012588752 @default.
• W2164521421 creator A5015063062 @default.
• W2164521421 creator A5016111941 @default.
• W2164521421 creator A5059326304 @default.
• W2164521421 creator A5069603059 @default.
• W2164521421 creator A5090344796 @default.
• W2164521421 date "2014-07-01" @default.
• W2164521421 modified "2023-09-30" @default.
• W2164521421 title "Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial" @default.
• W2164521421 cites W1525510378 @default.
• W2164521421 cites W1548346841 @default.
• W2164521421 cites W1831890944 @default.
• W2164521421 cites W1948043968 @default.
• W2164521421 cites W1982709222 @default.
• W2164521421 cites W1985025438 @default.
• W2164521421 cites W1996894458 @default.
• W2164521421 cites W2007748130 @default.
• W2164521421 cites W2022226231 @default.
• W2164521421 cites W2026162369 @default.
• W2164521421 cites W2029126847 @default.
• W2164521421 cites W2036030218 @default.
• W2164521421 cites W2037182281 @default.
• W2164521421 cites W2100420697 @default.
• W2164521421 cites W2104355586 @default.
• W2164521421 cites W2125234927 @default.
• W2164521421 cites W2133479239 @default.
• W2164521421 cites W2135719284 @default.
• W2164521421 cites W2155433659 @default.
• W2164521421 cites W2162670607 @default.
• W2164521421 cites W2238096017 @default.
• W2164521421 cites W2325674170 @default.
• W2164521421 cites W2470097850 @default.
• W2164521421 cites W4231905096 @default.
• W2164521421 cites W4248450786 @default.
• W2164521421 doi "https://doi.org/10.1016/s0140-6736(14)60157-4" @default.
• W2164521421 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4181666" @default.
• W2164521421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24702835" @default.
• W2164521421 hasPublicationYear "2014" @default.
• W2164521421 type Work @default.
• W2164521421 sameAs 2164521421 @default.
• W2164521421 citedByCount "162" @default.
• W2164521421 countsByYear W21645214212014 @default.
• W2164521421 countsByYear W21645214212015 @default.
• W2164521421 countsByYear W21645214212016 @default.
• W2164521421 countsByYear W21645214212017 @default.
• W2164521421 countsByYear W21645214212018 @default.
• W2164521421 countsByYear W21645214212019 @default.
• W2164521421 countsByYear W21645214212020 @default.
• W2164521421 countsByYear W21645214212021 @default.
• W2164521421 countsByYear W21645214212022 @default.
• W2164521421 countsByYear W21645214212023 @default.
• W2164521421 crossrefType "journal-article" @default.
• W2164521421 hasAuthorship W2164521421A5003436141 @default.
• W2164521421 hasAuthorship W2164521421A5003758047 @default.
• W2164521421 hasAuthorship W2164521421A5009660168 @default.
• W2164521421 hasAuthorship W2164521421A5010698227 @default.
• W2164521421 hasAuthorship W2164521421A5012588752 @default.
• W2164521421 hasAuthorship W2164521421A5015063062 @default.
• W2164521421 hasAuthorship W2164521421A5016111941 @default.
• W2164521421 hasAuthorship W2164521421A5059326304 @default.
• W2164521421 hasAuthorship W2164521421A5069603059 @default.
• W2164521421 hasAuthorship W2164521421A5090344796 @default.
• W2164521421 hasBestOaLocation W21645214212 @default.
• W2164521421 hasConcept C126322002 @default.
• W2164521421 hasConcept C131872663 @default.
• W2164521421 hasConcept C141071460 @default.
• W2164521421 hasConcept C142724271 @default.
• W2164521421 hasConcept C168563851 @default.
• W2164521421 hasConcept C204787440 @default.
• W2164521421 hasConcept C27081682 @default.
• W2164521421 hasConcept C2777628954 @default.
• W2164521421 hasConcept C2778376644 @default.
• W2164521421 hasConcept C2779234561 @default.
• W2164521421 hasConcept C29456083 @default.
• W2164521421 hasConcept C46973012 @default.
• W2164521421 hasConcept C54355233 @default.
• W2164521421 hasConcept C71924100 @default.
• W2164521421 hasConcept C86803240 @default.
• W2164521421 hasConceptScore W2164521421C126322002 @default.
• W2164521421 hasConceptScore W2164521421C131872663 @default.
• W2164521421 hasConceptScore W2164521421C141071460 @default.
• W2164521421 hasConceptScore W2164521421C142724271 @default.
• W2164521421 hasConceptScore W2164521421C168563851 @default.
• W2164521421 hasConceptScore W2164521421C204787440 @default.
• W2164521421 hasConceptScore W2164521421C27081682 @default.
• W2164521421 hasConceptScore W2164521421C2777628954 @default.
• W2164521421 hasConceptScore W2164521421C2778376644 @default.
• W2164521421 hasConceptScore W2164521421C2779234561 @default.
• W2164521421 hasConceptScore W2164521421C29456083 @default.
• W2164521421 hasConceptScore W2164521421C46973012 @default.
• W2164521421 hasConceptScore W2164521421C54355233 @default.
• W2164521421 hasConceptScore W2164521421C71924100 @default.

• next